Sutro Biopharma (STRO)
Develops site-specific and dual-payload antibody-drug conjugates for oncology using cell-free protein synthesis.
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.
Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO
Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 42.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,519 shares of the company's stock after purchasing an additional 321,137 shares during the
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif.
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after Citizens Jmp raised their price target on the stock from $23.00 to $35.00. Citizens Jmp currently has a market outperform rating on the stock. Sutro Biopharma traded as high as $32.58 and last traded at $32.3910. 120,254 shares traded
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of "Hold" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages
Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommendation of "Hold" from the eight research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to
Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript
Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation November 12, 2025 10:00 AM EST Company Participants Jane Chung - CEO & Director Jonathan Fawcett Anthony Tolcher Hans-Peter Gerber - Chief Scientific Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Greetings.
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.59 per share a year ago.
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.